October 2006
Worldwide Biotech;Oct2006, Vol. 18 Issue 10, p7
Trade Publication
The article reports on the completion of patient enrollment by Oncolytics Biotech Inc. for the Phase I U.S. clinical trial investigating the systemic delivery of Reolysin to patients with advanced cancers in 2006. It reveals the number of patients who were treated in the Phase I trial with Reolysin. Moreover, the administration of Reolysin among patients is described.


Related Articles

  • From the Bedside to the Bedside.'.  // BioWorld Today;11/18/2009, Vol. 20 Issue 223, p7 

    This article deals with the updated results obtained by Oncolytics Biotech Inc. from a Phase I/II trial of Reolysin in Great Britain. According to the study, the drug was well tolerated in patients with advanced cancers when combined paclitaxel/carboplatin. A total clinical benefit rate of 74%...

  • Oncolytics Biotech Signs Sponsorship Pact with CTG.  // Worldwide Biotech;Jun2012, Vol. 24 Issue 6, p5 

    The article reports that Calgary, Alberta-based Oncolytics Biotech Inc. has signed an agreement with National Crime Information Center (NCIC) Clinical Trials Group (CTG), wherein, CTG will sponsor and conduct a randomized phase II study of Reolysin® in patients with metastatic colorectal...

  • CLINIC ROUNDUP.  // BioWorld Today;5/27/2010, Vol. 21 Issue 102, p5 

    This section offers news briefs concerning clinical trials, including the enrollment in a Phase IIb trial to be conducted by EpiCept Corp., the completion of the enrollment in the Phase IIA proof-of-concept trial of Aganocide by NovaBay Pharmaceuticals Inc. and a patient enrollment by Oncolytics...

  • CLINIC ROUNDUP.  // BioWorld Today;4/26/2010, Vol. 21 Issue 79, p2 

    This section offers news briefs on clinical trials including the start of a Phase II trial by Affiris AG for its Alzheimer's disease vaccine candidate and completion by Oncolytics Biotech Inc. of Phase I enrollment in its trial of Reolysin in patients with recurrent malignant gliomas.

  • CLINIC ROUNDUP.  // BioWorld Today;6/23/2008, Vol. 19 Issue 121, p8 

    This section offers news briefs concerning the biopharmaceutical industry. The Phase II trial of intravenous Reolysin in combination with paclitaxel and carboplatin was launched by Oncolytics Biotech Inc. A deal was made by Pharmaxis Ltd. with the U.S. Food and Drug Administration (FDA) for a...

  • Clinic Roundup.  // BioWorld Today;3/ 6/2013, Vol. 24 Issue 43, p6 

    The article offers world news briefs related to clinical trials. Galectin Therapeutics Inc. revealed the U.S. Food & Drug Administration's (FDA) clearance on its Phase I trial of GR-MD-02 in subjects with non-alcoholic steatohepatitis. Oncolytics Biotech Inc. unveiled the completion of patient...

  • Oncolytics Biotech Trial Reports Positive Results.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p6 

    The article discusses the preliminary results reported by Oncolytics Biotech Inc. regarding the Phase 2 clinical trials of its REOLYSIN as of August 2011. Oncolytics is a Canadian-based firm and its new drug, taken intravenously with paclitaxel and carboplatin, showed promising results in its...

  • Wall Street 'Reolysin' Value; Oncolytics Soars on Phase III. Osborne, Randy // BioWorld Today;12/14/2012, Vol. 23 Issue 242, p1 

    This article reports on the impact of Oncolytics Biotech Inc.'s early Phase III results with Reolysin for head and neck cancer on the company's shares on December 13, 2012. The company's shares increased to 40 percent, or 86 cents, to close at 3.03 U.S. dollars after trading as high as 3.85 U.S....

  • Clinic Roundup.  // BioWorld Today;11/30/2010, Vol. 21 Issue 230, p7 

    This section offers news briefs related to clinical trials, including the agreement between the Medicines Co. and the Food and Drug Administration (FDA) for a Phase III program with oritavancin, viral suppression by Isentress based on a Phase III trial by Merck & Co. Inc. and Phase I trial of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics